In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Simulations Plus (SLP – Research Report). The company’s shares closed yesterday at $50.27.
Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Ligand Pharma, and Omnicell. According to TipRanks, Hewitt has an average return of 5.8% and a 44.90% success rate on recommended stocks.
Simulations Plus has an analyst consensus of Strong Buy, with a price target consensus of $61.00.
See the top stocks recommended by analysts >>
Based on Simulations Plus’ latest earnings release for the quarter ending May 31, the company reported a quarterly revenue of $16.23 million and a net profit of $4.01 million. In comparison, last year the company earned a revenue of $14.96 million and had a net profit of $4.09 million
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SLP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.
Read More on SLP:
- Simulations Plus management to meet with BTIG
- Simulations Plus sees FY23 EPS 63c-67c, consensus 65c
- Simulations Plus reports Q3 EPS 20c, consensus 20c
- Simulations Plus (SLP) Q3 Earnings Cheat Sheet
- ‘When Overbought Is Bullish’: Oppenheimer Sees S&P Uptrend Reaching 4,600 — Here Are 2 ‘Strong Buy’ Stocks to Bet on It
